Holen Sie sich die Stockscreener-App
2.21
5.74%
-0.14
Schlusskurs vom Vortag:
$2.35
Offen:
$2.36
24-Stunden-Volumen:
168.58K
Relative Volume:
0.53
Marktkapitalisierung:
$145.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.84M
KGV:
-4.5576
EPS:
-0.4849
Netto-Cashflow:
$-23.88M
1W Leistung:
+5.48%
1M Leistung:
-13.48%
6M Leistung:
-59.80%
1J Leistung:
+67.80%
1-Tages-Spanne:
$2.17
$2.3848
1-Wochen-Bereich:
$2.08
$2.40
52-Wochen-Spanne:
$1.21
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.215 | 146.80M | 0 | -30.84M | -23.88M | -0.4849 |
VRTX
Vertex Pharmaceuticals Inc
|
441.11 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.76 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.22 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
290.73 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.78 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Galectin Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Galectin Therapeutics (GALT) Fairly Valued After Q1 2026 Earn - GuruFocus
Belapectin reduces liver stiffness in high-risk MASH cirrhosis trial - Stock Titan
Galectin Therapeutics reports Q1 2026 net loss of $5.1M, cash $14.1M; updates belapectin program - TradingView
Galectin Therapeutics 1Q 2026: Financials Not Reported — 10-Q Summary - TradingView
Galectin Therapeutics (NASDAQ: GALT) trims Q1 2026 loss as R&D falls - Stock Titan
Galectin Therapeutics (NASDAQ: GALT) narrows Q1 2026 loss but leans on large convertible debt - Stock Titan
Will Galectin's New MASH Cirrhosis Data Renew Stock Momentum? - RTTNews
Galectin Therapeutics (GALT) Highlights Promising Phase 2b Trial Results - GuruFocus
Galectin Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Galectin Therapeutics announces publication of Navigate phase 2b trial results for belapectin in the Journal of Hepatology - marketscreener.com
Galectin publishes phase 2b trial results in Hepatology - Investing.com
Galectin Therapeutics Announces Publication Of Navigate Phase 2B Trial Results For Belapectin In The Journal Of Hepatology - TradingView
Galectin publishes phase 2b trial results in Hepatology By Investing.com - Investing.com Canada
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - Yahoo Finance
Why Galectin Therapeutics (GALT) guidance matters more than actual results | Q4 2025: Better Than ExpectedEarnings Analysis - newser.com
Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AA - Yahoo
GALT Stock Price, Quote & Chart | GALECTIN THERAPEUTICS INC (NASDAQ:GALT) - ChartMill
Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Galectin Therapeutics (GALT) upgraded to buy: What does it mean for the stock? - MSN
GALT Price Today: Galectin Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
What are the key catalysts for Galectin Therapeutics (GALT) stock (Drifts Higher) 2026-04-23Post Earnings - newser.com
GALT (Galectin Therapeutics Inc.) Q4 2025 narrower than expected loss drives 8.41 percent share gain amid positive investor sentiment.Earnings Per Share - UBND thành phố Hải Phòng
GALT (Galectin Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares gain 3.64 percent on upbeat investor reaction.Expert Momentum Signals - UBND thành phố Hải Phòng
Is institutional money buying Galectin Therapeutics (GALT) stock (Smart Money Exits) 2026-04-20Open Stock Signal Network - UBND thành phố Hải Phòng
Buy Signal: What is the long term forecast for Galectin Therapeutics Inc stockTrade Analysis Report & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Targets Report: Whats next for Galectin Therapeutics Inc stockBond Market & Weekly Setup with High ROI Potential - baoquankhu1.vn
Dip Buying: Can Galectin Therapeutics Inc weather a recession2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Reacting to Market | Price at $2.37, Up 6.76%Profit Surge - newser.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Earnings Risk: Is Galectin Therapeutics Inc stock a buy or sell2026 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Trend Recap: What is the long term forecast for Galectin Therapeutics Inc stock2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
Is Galectin Therapeutics (GALT) Stock Worth Holding | Price at $2.61, Down 2.25%Community Breakout Alerts - newser.com
Galectin Therapeutics (GALT) Eps Diluted (TTM) - Zacks Investment Research
Galectin Therapeutics Inc. (PHPN.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Galectin Therapeutics (GALT) Receives Buy Rating: How Will This Impact the Shares? - Bitget
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics - National Today
FY2026 Earnings Estimate for GALT Issued By HC Wainwright - marketbeat.com
Aug PostEarnings: Can Galectin Therapeutics Inc reach all time highs this year2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
What is HC Wainwright's Estimate for GALT Q1 Earnings? - MarketBeat
Galectin Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):